Study of DZD8586 for adults with chronic ITP
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with persistent or chronic primary ITP (immune thrombocytopenia).
- Your average platelet count is below 30,000 (based on at least two recent blood tests).
- You have tried at least one standard ITP treatment (such as steroids or IVIG) and it didn't work.
- You are not pregnant or breastfeeding, and you are willing to follow birth control rules if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how many cycles of high-dose dexamethasone (a steroid) work best for adults newly diagnosed with ITP, a condition that causes low platelets and bruising or bleeding. The goal is to find the right dose schedule to safely raise platelet counts.
This trial tests an investigational drug called CID-103 for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It aims to find the right dose and see if it can safely increase platelet counts to reduce bleeding risk.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
This trial tests a new tablet called TQB3473 for adults with persistent or long-lasting primary ITP. It is for people whose platelet counts stay low despite past treatments, and aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
This trial tests an intravenous immunoglobulin (IVIg) treatment for adults who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if this treatment can safely raise your platelet count.
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.